Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON-Reference-Cited by-同舟云学术

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON

Published:2019-01 Issue:1 Volume:7 Page:60-68
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Crestani Bruno,Huggins John T,Kaye Mitchell,Costabel Ulrich,Glaspole Ian,Ogura Takashi,Song Jin Woo,Stansen Wibke,Quaresma Manuel,Stowasser Susanne,Kreuter Michael

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference25 articles.

1. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management;Raghu;Am J Respir Crit Care Med,2011

3. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study;Fernández Pérez;Chest,2010

4. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11;Raghu;Lancet Respir Med,2014

5. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report;Collard;Am J Respir Crit Care Med,2016

Cited by 175 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial;American Journal of Respiratory and Critical Care Medicine;2024-08-15

2. Deciphering the mediating role of CXCL10 in hypothyroidism-induced idiopathic pulmonary fibrosis in European ancestry: a Mendelian randomization study;Frontiers in Immunology;2024-08-09

3. Enhancing Outcomes in Chronic Fibrotic Interstitial Lung Disease Through Aggressive Management of Nintedanib-Induced Adverse Drug Reactions: A Retrospective Analysis;Drugs - Real World Outcomes;2024-08-05

4. The dorsal muscle group area at the T12 vertebral level as a risk factor for tolerability of nintedanib in patients with idiopathic pulmonary fibrosis or other progressive fibrosing interstitial lung diseases;Medicine;2024-07-12

5. Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis;European Journal of Clinical Pharmacology;2024-07-04